Evoke Pharma (STU:EV00) 3-Year EBITDA Growth Rate : 29.20% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Evoke Pharma 3-Year EBITDA Growth Rate?

Evoke Pharma's EBITDA per Share for the three months ended in Dec. 2023 was €-0.51.

During the past 3 years, the average EBITDA Per Share Growth Rate was 29.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 18.00% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 21.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Evoke Pharma was 35.80% per year. The lowest was -1.20% per year. And the median was 16.75% per year.

Competitive Comparison of Evoke Pharma's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Evoke Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evoke Pharma's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evoke Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Evoke Pharma's 3-Year EBITDA Growth Rate falls into.

Evoke Pharma 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Evoke Pharma (STU:EV00) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Evoke Pharma 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Evoke Pharma (STU:EV00) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (STU:EV00) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

EVOK:USA

Address

420 Stevens Avenue, Suite 370, Solana Beach, CA, USA, 92075

Website

https://www.evokepharma.com

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma (STU:EV00) Headlines

No Headlines